NK
Showing 1 - 25 of 3,975
Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)
Recruiting
- Extranodal NK T Cell Lymphoma
- NK-Cell Leukemia
- Anti-CD56 CAR T
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023
AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- CD33/CLL1 dual CAR-NK cell
- +5 more
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Aug 4, 2023
Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)
Not yet recruiting
- Synovial Sarcoma
- Fludarabine phosphate
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))
Recruiting
- Immunotherapy
- Multiple Myeloma
- Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Dec 14, 2022
Multiple Myeloma, Plasma Cell Leukemia Trial in Shanghai (Human BCMA targeted CAR-NK cells injection)
Recruiting
- Multiple Myeloma
- Plasma Cell Leukemia
- Human BCMA targeted CAR-NK cells injection
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Sep 13, 2023
Leukemia Trial (Donor Enriched Activated Natural Killer Cell Infusion)
Withdrawn
- Leukemia
- Donor Enriched Activated Natural Killer Cell Infusion
- (no location specified)
Dec 20, 2022
Ovarian Cancer Trial in Hangzhou (NKG2D CAR-NK)
Recruiting
- Ovarian Cancer
- NKG2D CAR-NK
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Mar 26, 2023
AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)
Recruiting
- AML, Adult
- CLL1 CAR-NK cell injection
-
Hangzhou, Zhejiang, ChinaClinical research ethics committee of the first affiliated hospi
Aug 30, 2023
NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)
Not yet recruiting
- NK Cell
- +2 more
- autologous NK cell
-
Hubei, Xiangyang, ChinaEC of Xiangyang No.1 People's Hospital Hubei University of Medic
Jun 19, 2023
NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen
Not yet recruiting
- NK-T-Cell Lymphoma, Extranodal
- 4 cycles of ESA regimen with sandwiched radiotherapy
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital
Sep 29, 2023
Malignant Sarcoma Trial in Madrid (Natural Killer (NK) cells (a new immunotherapy))
Recruiting
- Malignant Sarcoma
- Natural Killer (NK) cells (a new immunotherapy)
-
Madrid, SpainHospital Universitario La Paz
Jul 19, 2023
Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)
Not yet recruiting
- Myeloma
- Fludarabine phosphate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 27, 2023
Aggressive NK Cell Leukemia Trial in Hiroshima (PPMX-T003)
Recruiting
- Aggressive NK Cell Leukemia
-
Hiroshima, JapanHiroshima University Hospital
May 9, 2023
Osteosarcoma, Soft Tissue Sarcoma Trial in Shanghai (NK510)
Recruiting
- Osteosarcoma
- Soft Tissue Sarcoma
-
Shanghai, ChinaShanghai General Hospital
Oct 31, 2023
Solid Tumors Trial in Houston (Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate)
Not yet recruiting
- Solid Tumors
- Rimiducid
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Sep 27, 2023
Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted
Recruiting
- Acute Myeloid Leukemia
- +3 more
- CD123 targeted CAR-NK cells
-
Taiyuan, Shanxi, ChinaShanxi Bethune Hospital
Aug 28, 2023
nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)
Recruiting
- nk/T-cell Lymphoma
- +2 more
- XPO1 inhibitor
-
Beijing, Haidian, ChinaChinaPLAGH
Apr 18, 2023
Colorectal Cancer Trial (anesthetic method)
Withdrawn
- Colorectal Cancer
- anesthetic method
- (no location specified)
Jul 11, 2023
Acute Myeloid Leukemia Trial in Houston (Azacitidine, Venetoclax, NK Cells)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +2 more
-
Houston, TexasM.D. Anderson Cancer Center
Apr 17, 2023
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)
Recruiting
- Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
- dualCAR-NK19/70 cell
-
Shanghai, Shanghai, ChinaShanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in Columbus (procedure, drug, biological)
Not yet recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- HER2-Negative Breast Carcinoma
- Biospecimen Collection
- +5 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Aug 30, 2023
Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)
Not yet recruiting
- Extranodal NK/T-cell Lymphoma
- Sugemalimab
- +4 more
- (no location specified)
Jan 17, 2023
T-Cell and NK-Cell Tumor Trial
Not yet recruiting
- T-Cell and NK-Cell Neoplasm
- (no location specified)
Sep 28, 2023
NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride
Not yet recruiting
- NK-T-Cell Lymphoma, Extranodal
- Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
- (no location specified)
Mar 7, 2023
B-Cell Lymphoblastic Leukemia/Lymphoma Trial in Kunming (Anti-CD19 UCAR-NK cells)
Recruiting
- B-Cell Lymphoblastic Leukemia/Lymphoma
- Anti-CD19 UCAR-NK cells
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Dec 19, 2022